E3 Ligase Platforms

Dysregulated and/or mutated proteins are at the core of the development and progression of nearly every human disease. The levels of both normal and disease-associated proteins are controlled by the ubiquitin system as a natural process the body uses to maintain normal function of the cell.

Nurix Lab

Manipulation of the ubiquitin system and its component E3 ligases, the key enzymes responsible for controlling protein levels in human cells, could alter the outcome of numerous diseases. This discovery has led to our intensive focus on developing drugs that modulate this class of previously hard-to-drug enzymes.

Positioned at the forefront of drug development for protein regulation, Nurix has leveraged its deep E3 ligase expertise to develop two complementary platforms that either inhibit ligases or harness ligases to control target protein levels. The broad scope of Nurix’s discovery platforms, powered by proprietary DNA-encoded libraries and screening capabilities, differentiates Nurix from other companies developing therapies that target protein degradation.

The broad scope of Nurix’s discovery platforms, powered by proprietary DNA-encoded libraries and screening capabilities, differentiates Nurix from other companies developing therapies that target protein degradation.

The Ubiquitin Proteasome System (UPS): Regulating the Body’s Cellular Protein Levels

UPS
  • The levels of both normal and disease-associated proteins are regulated by the ubiquitin system and its component E3 ligases to maintain normal function of the cell
  • Dysregulated and/or mutated proteins are at the core of the development and progression of nearly every human disease
  • Drugs that can modulate the ubiquitin system and its component E3 ligases to control protein levels could alter the outcome of many diseases

Two Complementary Drug Platforms That Modulate E3 Ligases

Inhibit

  • Nurix’s small molecule drug harnesses an E3 ligase to ubiquitinate disease-associated dysregulated proteins.
  • After ubiquitination, dysregulated proteins are degraded by the proteasome, leading to a reduction in target protein levels.
Inhibit

  • Nurix’s small molecule drug inhibits an E3 ligase to block the ubiquitination and subsequent degradation of a target protein, leading to an increase in target protein levels.

Two Complementary Platforms to Develop Drugs That Modulate the Activity of E3 Ligases

Two complementary platforms to develop drugs that modulate the activity of E3 ligases